INNO-206 phase II b trial

General Blog
1

INNO-206 is a tumor-targeted doxorubicin conjugate. In other words, it is supposed to deliver doxorubicin more specifically to the tumor site (and hopefully prevent the toxicity to the heart...). The phase II b trial is supposed to start soon:

http://www.pharmabiz.com/NewsDetails.aspx?aid=66746&sid=2

http://www.cytrx.com/inno_206.html

2

Here is a link to the phase II b trial:

http://clinicaltrials.gov/ct2/show/NCT01514188?term=INNO-206&rank=2